Omar Ramla, Malfait Fransiska, Van Agtmael Tom
Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, G12 8QQ, UK.
Centre for Medical Genetics, Ghent University Hospital, Belgium.
Matrix Biol Plus. 2021 Nov 9;12:100090. doi: 10.1016/j.mbplus.2021.100090. eCollection 2021 Dec.
Vascular Ehlers Danlos (vEDS) syndrome is a severe multi-systemic connective tissue disorder characterized by risk of dissection and rupture of the arteries, gastro-intestinal tract and gravid uterus. vEDS is caused by mutations in , that encodes the alpha 1 chain of type III collagen, which is a major extracellular matrix component of the vasculature and hollow organs. The first causal mutations were identified in the 1980s but progress in our understanding of the pathomolecular mechanisms has been limited. Recently, the application of more refined animal models combined with global omics approaches has yielded important new insights both in terms of disease mechanisms and potential for therapeutic intervention. However, it is also becoming apparent that vEDS is a complex disorder in terms of its molecular disease mechanisms with a poorly understood allelic and mechanistic heterogeneity. In this brief review we will focus our attention on the disease mechanisms of mutations and vEDS, and recent progress in therapeutic approaches using animal models.
血管型埃勒斯-当洛综合征(vEDS)是一种严重的多系统结缔组织疾病,其特征为动脉、胃肠道和妊娠子宫有夹层形成和破裂的风险。vEDS是由COL3A1基因突变引起的,该基因编码III型胶原蛋白的α1链,III型胶原蛋白是血管系统和中空器官的主要细胞外基质成分。首个致病突变于20世纪80年代被发现,但我们对致病分子机制的理解进展有限。最近,更精细的动物模型与整体组学方法相结合的应用,在疾病机制和治疗干预潜力方面都产生了重要的新见解。然而,vEDS在分子疾病机制方面是一种复杂的疾病这一点也越来越明显,其等位基因和机制的异质性了解甚少。在这篇简短的综述中,我们将把注意力集中在COL3A1基因突变和vEDS的疾病机制,以及使用动物模型的治疗方法的最新进展上。